TME Pharma N.V. - Asset Resilience Ratio
TME Pharma N.V. (ALTME) has an Asset Resilience Ratio of 0.19% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See TME Pharma N.V. working capital to net assets to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2015–2025)
This chart shows how TME Pharma N.V.'s Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see TME Pharma N.V. balance sheet assets.
Liquid Assets Composition Over Time
This chart breaks down TME Pharma N.V.'s liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Explore long-term investment intensity of TME Pharma N.V. to see how much of total assets are deployed in long-term investments.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 0% |
| Short-term Investments | €4.00K | 0.19% |
| Total Liquid Assets | €4.00K | 0.19% |
Asset Resilience Insights
- Limited Liquidity: TME Pharma N.V. maintains only 0.19% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
TME Pharma N.V. Industry Peers by Asset Resilience Ratio
Compare TME Pharma N.V.'s asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Abivax SA
PA:ABVX |
Biotechnology | 2.58% |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252 |
Biotechnology | 2.03% |
|
Neuren Pharmaceuticals Ltd
AU:NEU |
Biotechnology | 90.43% |
|
Lifecome Biochemistry Co Ltd
SHE:002868 |
Biotechnology | 4.69% |
|
Pulike Biological Engineering
SHG:603566 |
Biotechnology | 17.82% |
|
Rocket Pharmaceuticals Inc
NASDAQ:RCKT |
Biotechnology | 14.00% |
|
NEWRON PHARMACEUT. EO-20
XETRA:NP5 |
Biotechnology | 41.67% |
|
Upstream Bio, Inc.
NASDAQ:UPB |
Biotechnology | 64.70% |
Annual Asset Resilience Ratio for TME Pharma N.V. (2015–2025)
The table below shows the annual Asset Resilience Ratio data for TME Pharma N.V..
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 0.19% | €4.00K ≈ $4.68K |
€2.14 Million ≈ $2.50 Million |
-95.09pp |
| 2024-12-31 | 95.27% | €3.25 Million ≈ $3.79 Million |
€3.41 Million ≈ $3.98 Million |
+5.15pp |
| 2023-12-31 | 90.12% | €2.25 Million ≈ $2.62 Million |
€2.49 Million ≈ $2.91 Million |
+1.71pp |
| 2022-12-31 | 88.42% | €4.63 Million ≈ $5.42 Million |
€5.24 Million ≈ $6.13 Million |
-8.67pp |
| 2021-12-31 | 97.09% | €9.48 Million ≈ $11.09 Million |
€9.77 Million ≈ $11.42 Million |
+0.11pp |
| 2020-12-31 | 96.98% | €10.33 Million ≈ $12.08 Million |
€10.65 Million ≈ $12.46 Million |
+15.40pp |
| 2019-12-31 | 81.58% | €1.41 Million ≈ $1.65 Million |
€1.73 Million ≈ $2.02 Million |
-13.99pp |
| 2018-12-31 | 95.57% | €4.32 Million ≈ $5.05 Million |
€4.52 Million ≈ $5.28 Million |
+12.86pp |
| 2016-12-31 | 82.71% | €2.37 Million ≈ $2.77 Million |
€2.87 Million ≈ $3.35 Million |
+80.08pp |
| 2015-12-31 | 2.63% | €159.00K ≈ $185.89K |
€6.04 Million ≈ $7.06 Million |
-- |
About TME Pharma N.V.
TME Pharma N.V., a clinical-stage biopharmaceutical company, focuses on the development of proprietary therapeutics for the treatment of cancer in Germany. The company's Spiegelmer platform has a proprietary pipeline of clinical-stage product candidates, including its lead cancer drug candidate, NOX-A12, which is under development as a combination therapy for various cancer indications, such as m… Read more